Email this article Studying of the Mechanisms of Combined Effect of Dexamethasone, Doxorubicin, and Docetaxel on Breast Cancer Cells
- Authors: Dukhanina E.A.1, Portseva T.N.1,2, Dukhanin A.S.2, Georgieva S.G.1
-
Affiliations:
- V. A. Engelhard Institute of Molecular Biology, Russian Academy of Sciences
- N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 166, No 1 (2018)
- Pages: 54-57
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/240828
- DOI: https://doi.org/10.1007/s10517-018-4288-2
- ID: 240828
Cite item
Open Access
Access granted
Subscription Access
Abstract
The sensitivity of MDA-MB231 breast cancer cells to the effects of pharmacological agents was evaluated by their motility and viability. Dexamethasone, doxorubicin, or docetaxel administered separately in their effective concentration suppressed cell motility (in 16 h) and caused cell death (in 48 h). The strength of the effects increased in the following order: dexa methasone
About the authors
E. A. Dukhanina
V. A. Engelhard Institute of Molecular Biology, Russian Academy of Sciences
Author for correspondence.
Email: das03@rambler.ru
Russian Federation, Moscow
T. N. Portseva
V. A. Engelhard Institute of Molecular Biology, Russian Academy of Sciences; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: das03@rambler.ru
Russian Federation, Moscow; Moscow
A. S. Dukhanin
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: das03@rambler.ru
Russian Federation, Moscow
S. G. Georgieva
V. A. Engelhard Institute of Molecular Biology, Russian Academy of Sciences
Email: das03@rambler.ru
Russian Federation, Moscow
Supplementary files
